Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025282 | 0.84 | MAPT (0.65) | MAPTRAB9AALDH1A1ERN1 | |
| SCHEMBL2947694 | 0.84 | TDP1 (0.61) | TP53LDHANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14988369 | 0.84 | NPC1 (0.50) | KEAP1NFE2L2KDM4EMAPTNPC1 | |
| SCHEMBL6231939 | 0.83 | RAB9A (0.60) | KEAP1NFE2L2MAPTNPC1RAB9A | |
| SCHEMBL71038 | 0.81 | LMNA (0.54) | KDM4ELDHAMAPTNPC1PKM | |
| SCHEMBL1279957 | 0.81 | MAPT (0.56) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL629211 | 0.80 | TP53 (0.67) | TP53KEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL8686215 | 0.80 | TP53 (0.67) | TP53KEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL14988297 | 0.80 | POLB (0.63) | LDHAMAPTNPC1RAB9A | |
| SCHEMBL31243316 | 0.80 | LDHA (0.77) | LDHANPC1RAB9ASMN1; SMN2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727808-B3 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-1727808-B1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| EP-1727808-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | Spirogen Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005085177-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | TP53 866/4885KEAP1 1187/4885NFE2L2 919/4885 |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | PCNA, POLL, XPA | TP53 163/4885KEAP1 1009/4885NFE2L2 555/4885 |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | PCNA, POLL, DNA2 | TP53 161/4885KEAP1 963/4885NFE2L2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.